X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Comment | User-defined comments for dose data. | ILX:0103522 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Grid Scaling | Scaling factor that when multiplied by the dose grid data found in Pixel Data (7FE0,0010) attribute of the , yields grid doses in the dose units as specified by Dose Units (3004,0002). | ILX:0103523 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Rate Delivered | Dose Rate actually delivered for segment beginning at current control point (meterset/min). | ILX:0103524 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Rate Set | Dose Rate to be set on treatment machine for segment beginning at current control point (e.g. MU/min). | ILX:0103525 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Description | User-defined description of Dose Reference. | ILX:0103526 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Number | Identification number of the Dose Reference. The value of Dose Reference Number (300A,0012) shall be unique within the RT Plan in which it is created. Required if Dose Reference Sequence (300A,0012) is sent. | ILX:0103527 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Point Coordinates | Coordinates (x,y,z) of Reference Point in the patient based coordinate system described in (mm). | ILX:0103528 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Reference Sequence | Introduces sequence of Dose References. One or more items may be included in this sequence. | ILX:0103529 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Reference Structure Type | Structure type of Dose Reference. | ILX:0103530 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Reference Type | Type of Dose Reference. | ILX:0103531 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Reference UID | A unique identifier for a Dose Reference that can be used to link the same entity across multiple RT Plan objects. | ILX:0103532 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Summation Type | Type of dose summation. | ILX:0103533 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Type | Type of dose. | ILX:0103534 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dose Units | Dose axis units. | ILX:0103535 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Dose Value | Dose value for ROI, in units defined by Dose Units (3004,0002). Dose Value (3004,0012) shall be the dose value corresponding to the referenced isodose curve, named dose point, or unnamed dose point. | ILX:0103536 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dot pattern expectancy task | No definition submitted yet. | ILX:0103537 | 6 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Doublecortin | A cytoplasmic protein which appears to direct neuronal migration by regulating the organization and stability of microtubules. The encoded protein contains two doublecortin domains, which bind microtubules. In addition, the encoded protein interacts with LIS1, the regulatory gamma subunit of platelet activating factor acetylhydrolase, and this interaction is important to proper microtubule function in the developing cortex (Entrez Gene definition: GeneID: 1641. | ILX:0103538 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Down | A direction from a higher point to a lower point. | ILX:0103539 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Downs syndrome | A disorder caused by the presence of all or part of an extra 21st chromosome, characterized by structural abnormalities throughout the body. Often Down syndrome is associated with some impairment of cognitive ability and physical growth as well as facial appearance. (Adapted from Wikipedia) | ILX:0103540 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Doxacurium chloride | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. Pharmacology: Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of anticholinesterase required for recovery of neuromuscular function. Doxacurium chloride is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine. Mechanism of action: Doxacurium chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. Drug type: Approved. Small Molecule. Drug category: Neuromuscular Nondepolarizing Agents | ILX:0103541 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X